By SquaredTown on May 29, 2026
Phase 1a/b Study for Selective Brain-Penetrant CDK2 Inhibitor AL-605 doses patients; Selective Brain-Penetrant CDK4 Inhibitor AL-433 on Track for First-in-Human Study SAN DIEGO, May 29, 2026 /PRNewswire/ -- Alaw Therapeutics, Inc. ("Alaw"), a clinical-stage biotechnology company...